Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals
2006 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
TTPH STOCK SYMBOL
$2.29 SHARE PRICE (As of Friday Closing)
Description

Tetraphase Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is XERAVA (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 480 Arsenal Street
  • Suite 110
  • Watertown, MA 02472
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tetraphase Pharmaceuticals’s full profile, request a free trial.

Tetraphase Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.06 - $33.40 $6.91M $2.25 -$29.70 110K 3.02M

Tetraphase Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value (22,072) (36,362) 162,547 (13,351)
Revenue 9,970 18,904 9,666 5,145
EBITDA (77,958) (72,705) (115,284) (77,198)
Net Income (80,194) (72,158) (114,752) (77,480)
Total Assets 42,280 122,944 149,040 151,710
Total Debt 5,347 28,291 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tetraphase Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Tetraphase Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Tetraphase Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Tetraphase Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Tetraphase Pharmaceuticals Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SCYNEXIS Formerly VC-backed Durham, NC 00 00000 000000000 00000
00 000000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000&0 00000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
000000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 00.000 00000000 00.000
To view this company’s complete list of competitors, request access »

Tetraphase Pharmaceuticals Executive Team (12)

Name Title Board
Seat
Contact
Info
Larry Edwards Chief Executive Officer & President
Maria Stahl General Counsel & Executive
Erik Phillips Executive

9 Former Executives

You’re viewing 3 of 12 executives. Get the full list »

Tetraphase Pharmaceuticals Board Members (12)

Name Representing Role Since Contact
Info
Garen Bohlin Self Board Member 000 0000
Guy Macdonald Tetraphase Pharmaceuticals Board Member 000 0000
Jeffrey Chodakewitz MD Self Board Member 000 0000
John Freund MD Self Board Member 000 0000
Nancy Wysenski Self Board Member 000 0000

6 Former Board Members

You’re viewing 5 of 12 board members. Get the full list »